**The genetic architecture of postoperative delirium after major surgery and its relationship with non-postoperative neurocognitive conditions**

Richard A. Armstrong,[1*] Paul Yousefi,[1,2] Ben Gibbison,[3] Golam M Khandaker,[1,2,4,5] Tom R Gaunt[1,2]

1 MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK.

2 NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.

3 Bristol Medical School, University of Bristol, Bristol, UK.

4 Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK.

5 Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

**\*Correspondence to:** Richard A Armstrong

**Email:** ra17848@bristol.ac.uk

**X:** @drrichstrong

**Short title:** Genetic architecture of postoperative delirium

**Keywords:** Genome-wide association study; Genetics; Postoperative delirium; UK Biobank; Risk factors

**Abstract**

**Background**

Postoperative delirium is the most common postoperative complication in older individuals. Genome-wide association studies (GWAS) can provide insights into how genetic factors influence postoperative risk. We examined the genetic architecture of postoperative delirium after major surgery and its relationship with related cognitive conditions (delirium of any type and Alzheimer's disease, including the *APOE* ε4 allele).

**Methods**

A GWAS was performed in UK Biobank to identify genetic variants associated with postoperative delirium. These results were then used in genetic correlation and polygenic risk score analyses to investigate shared genetic risk between postoperative delirium and a) delirium of all causes, and b) Alzheimer's disease.

**Results**

The GWAS (1016 cases, 139,148 controls) identified six Single Nucleotide Polymorphisms (SNPs) that mapped to four genes (*APOE, TOMM40, APOC1* and *PVRL2*); $p < 5 \times 10^{-8}$. Five SNPs remained significant after excluding pre-existing dementia, and two after excluding subsequent dementia. The lead SNP was rs429358, a missense variant of *APOE*. Genetic correlation and polygenic risk score analyses revealed evidence of shared genetic architecture and risk between postoperative delirium and Alzheimer's disease (rho = 0.68, p<0.001). The *APOE* ε4 isoform had a dose-response effect on risk (OR [95% CI] for one and two copies 1.75 [1.53 – 2.0] and 4.19 [3.25 – 5.41] respectively, p <0.001).

**Conclusions**

We identified genetic variants associated with increased risk of postoperative delirium. We also found evidence of shared genetic liability with Alzheimer's disease suggesting that individuals with genetic risk of Alzheimer's disease, even without symptoms, may be at higher risk of postoperative delirium.

**Introduction**

Postoperative delirium is the most common postoperative complication in older

individuals, with an incidence of up to 65% [1,2]. It has substantial health and

resource implications including increased morbidity, mortality and healthcare costs

[1,3]. Hypotheses of the underlying mechanisms span a range of pathways including

release of excitotoxic neurotransmitters, neuronal injury and inflammation,

physiological stressors, metabolic derangements, electrolyte disorders and genetic

factors [1,2,4–8]. Postoperative delirium has been associated with an increased risk

of cognitive decline and incident dementia [9] but there is conflicting evidence on

how the acute occurrence of postoperative delirium interacts with longer-term

cognitive decline and neurodegeneration [10].

Whilst the aging global population and increasing numbers of older adults

undergoing surgery have made perioperative brain health an increasing focus of

research and clinical initiatives [11], the ability of clinical teams to produce

personalised assessments of clinical risk for individuals remains limited. Improved

detection of underlying biological risk in conjunction with established clinical risk

factors could aid in preoperative risk prediction, facilitate better-informed shared-

decision making and allow targeting of multicomponent interventions to prevent

delirium [11] with potential reductions in morbidity, mortality and resource utilisation.

Population-based genome-wide association studies (GWAS)  are a powerful

approach for  identifying genetic risk factors associated with complex conditions of

multifactorial aetiology.  Their results can aid prediction but also identify underlying

biological mechanisms and potential targets for intervention. They have been extensively applied to a wide range of clinical phenotypes [12], but rarely to postoperative delirium specifically. Previous GWAS that have included postoperative neurocognitive complications have failed to identify any genome-wide significant associations [13–15] - most likely because they suffered from limited sample sizes and heterogeneity of outcomes.

This study aimed to evaluate the association between genetic variants genome-wide and postoperative delirium following major surgery, and to explore whether postoperative delirium shares genetic risk factors with related conditions, specificially delirium of all causes and Alzheimer's disease. The limitations of previous studies are addressed by defining a major surgery cohort in a large scale national biobank and focusing on a single outcome phenotype.

**Methods**

*Study Populations*

The data source for the primary analysis was UK Biobank, a long-term prospective

cohort study that provides a large-scale biomedical database and research resource

containing genetic, lifestyle and health information from half a million UK participants

recruited between 2006 and 2010 (http://www.ukbiobank.ac.uk). The UK Biobank

study was approved by the North-West Multi-centre Research Ethics Committee and

all participants provided written informed consent [16]. Additionally, publicly available

GWAS summary statistics from the FinnGen study were used as an external cohort

for genetic correlation analyses. FinnGen is a large-scale genomics initiative that has

analysed over 500,000 Finnish biobank samples and correlated genetic variation

with health data to understand disease mechanisms and predispositions. The project

is a collaboration between research organisations and biobanks within Finland and

international industry partners [17].

*Genotyping*

UK Biobank genotyping was performed by Affymetrix using two purpose-designed

arrays. Genotype data were quality controlled, phased and ~96 million genotypes

were imputed using the Haplotype Reference Consortium and UK10K haplotype

resources. FinnGen genotyping used a ThermoFisher Axiom custom chip array with

imputation to a reference dataset derived from Finnish whole-genome sequences.

Further information on the methods and QC pipelines are available [16,18].

*Inclusion and exclusion criteria*

Eligible participants were those undergoing major, inpatient surgery after their date of enrolment in UK Biobank. Linked hospital inpatient data is available for all UK Biobank participants with follow-up to 31 May 2022 for Wales, 31 August 2022 for Scotland and 31 October 2022 for England [19]. Major surgery was defined by OPCS4 code using the Bupa Schedule of Procedures and Abbott classification [20,21] and diagnoses of delirium were identified using International Classification of Diseases, Tenth Revision (ICD-10) code F05. Exclusion criteria included planned day case surgery and a previous diagnosis of delirium (see Supplementary Methods for more detail on phenotype definition and exclusions).

*Outcome definition*

The primary outcome was a first diagnosis of delirium within 30 days of surgery. Controls were defined as those undergoing major surgery with no delirium diagnosis within 30 days.

*Genome-wide Association Study (GWAS)*

Case–control GWAS adjusted for sex, genetic chip and the first ten principal components was performed using regenie (v3.2.2) [22]. Quality control and ancestry definition were performed by previously established MRC-IEU workflows and methods [23]. Post-hoc analyses were conducted using Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA GWAS [24]). Independent significant SNPs were defined as those meeting a genome-wide significance threshold of $p < 5 \times 10^{-8}$ and independent of each other at $r^2 < 0.6$. Lead SNPs were

identified from independent significant SNPs at $r^2 < 0.1$. Gene-based analysis was performed using Multi-marker Analysis of GenoMic Annotation (MAGMA [25]).

Sensitivity analyses were performed as follows: a) with adjustment for age; b) after excluding participants who had a previous dementia diagnosis; and c) excluding participants who had a previous dementia diagnosis or were diagnosed with dementia after the index procedure.

*Post-GWAS follow-up analyses*

Exploratory follow-up analyses were informed by the results of the primary GWAS analysis. Two approaches were taken to formally assess shared genetic architecture between postoperative delirium and a) delirium of any type; b) Alzheimer's Disease: genetic correlation analysis and polygenic risk scoring.

*Genetic correlation analysis*

Genetic correlation analyses were performed between the UKB GWAS results presented here and the external FinnGen study cohort. GWAS summary statistics (Freeze 9, https://r9.finngen.fi/) were obtained for a) delirium (any cause); and b) Alzheimer's disease. Local Analysis of [co]Variant Association (LAVA [26]) was used to analyse bivariate local genetic correlation between these phenotypes and postoperative delirium (using the summary statistics from the primary GWAS analysis in UK Biobank).

*Polygenic risk score analysis*

Polygenic risk scores calculate a weighted sum of risk based on alleles associated with a disease or outcome phenotype. The Polygenic Score Catalog (https://www.pgscatalog.org/) was used to identify polygenic risk scores for Alzheimer's disease. No polygenic risk scores were identified for delirium. The *pgsc_calc* workflow [27] was used to download, variant match and calculate individual polygenic scores for the primary UK Biobank cohort. Individual scores were then centred and scaled before being summed and averaged. Odds ratios for the association between increasing quintile of polygenic risk score for Alzheimer's disease and postoperative delirium were estimated by logistic regression with adjustment for age and sex using the *glm* function in R (version 4.4.0).

*Apolipoprotein E (APOE) genotype analysis*

It has been recommended that the *APOE* region of chromosome 19 should be excluded from Alzheimer's disease polygenic risk scores, with the *APOE* ε4 allele included as an additional covariate in modelling, due to its outsize effect relative to other regions across the genome [28]. The subset of polygenic scores identified above which did not include the *APOE* region (defined as a 10 kilobase window either side of region from the start position of *TOMM40*, 45,394,477, to the stop position of *APOC1*, 45,422,606, build 37/hg19 [28]) were therefore considered in an additional analysis, adjusted for age, sex and *APOE* ε4 allele count (0, 1, 2).

**Results**

*Participant characteristics*

A total of 1016 cases of postoperative delirium and 139,148 controls were identified (Figure 1). Individuals who developed postoperative delirium tended to be older, male and had higher prevalence of comorbidities (Table 1). Compared to controls, a higher proportion of patients in the postoperative delirium group underwent emergency (532 (52%) vs 29,530 patients (21%)) and cardiothoracic surgery (172 (17%) vs 5041 patients (3.6%)).

*Genome-wide significant associations for postoperative delirium*

Six independent, statistically significant SNPs were identified within a single genetic risk region on chromosome 19 (Figure 2 and 3, Table 2). The lead SNP was rs429358, a missense variant in the *APOE* gene that, together with rs7412, defines the ε2/ε3/ε4 isoforms linked to Alzheimer's disease risk. A total of 26 genes were mapped to this region, including four (*APOE*, *TOMM40*, *APOC1* and *PVRL2*) that were significantly associated in MAGMA gene-level analysis (Supplementary table 2, Supplementary Figures 1 and 2). Adding age as an additional covariate in the GWAS identified one further independent significant SNP, rs12691088, an intronic variant of the *APOC1* gene (Supplementary table 3).

*GWAS results after excluding existing or incident dementia*

After excluding individuals with a pre-existing diagnosis of dementia (56 cases (5.7%) and 375 controls (0.3%)), 5 of the 6 independent significant SNPs remained significant. However, rs75627662 (a downstream variant of *APOE*) no longer

reached genome-wide significance. Three genes, *APOE*, *APOC1* and *TOMM40*, remained significant on MAGMA testing (Supplementary figure 3 and 4). When patients who went on to be diagnosed with dementia during UK Biobank follow-up were also excluded (141 cases, 13.9%, and 2358 controls, 1.7%), two SNPs remained genome-wide significant, rs429358 and rs157592. The MAGMA results were unchanged (Supplementary figure 5 and 6).

*Genetic correlation with Alzheimer's disease*

Significant local genetic correlation was identified on chromosome 19 between postoperative delirium and both delirium of all causes and Alzheimer's disease (Table 3). The correlated region (chr19:45040933-45893307) encompassed the independent significant SNPs from the primary GWAS.

*Association of genetic predisposition for Alzheimer's disease with postoperative delirium*

Prior to averaging, forty-two PGS for Alzheimer's disease were identified and passed variant matching (Supplementary Table 3). Increased polygenic risk for Alzheimer's disease was associated with increased risk of postoperative delirium in the UK Biobank cohort after adjusting for age and sex (adjusted OR [95% CI] PGS quintile 4: 1.49 [1.2-1.85], PGS quintile 5: 2.29 [1.87-2.8], p <0.001; Table 4).

*Effect of Apolipoprotein E (APOE) genotype on the association of Alzheimer's disease risk with postoperative delirium*

Fifteen of the polygenic risk scores identified for Alzheimer's disease contained no variants in the *APOE* region (*APOE*-independent scores, Supplementary table 4). The effect size of increasing PGS quintile was reduced compared to *APOE*-inclusive scores and the presence of one or more *APOE* ε4 isoforms was associated with increased risk of postoperative delirium (Table 4).

**Discussion**

In this study, using a large national biobank with linked healthcare data, we identified a genetic risk locus for postoperative delirium on chromosome 19 which included six independent significant SNPs and four mapped genes meeting genome-wide significance. Follow-up analyses in an independent cohort confirmed the presence of shared genetic risk between postoperative delirium and Alzheimer's disease.

Previous GWAS which have included postoperative delirium as an outcome have failed to find any genome-wide significant results, but were likely underpowered [13–15]. Our study, to the best of our knowledge the largest GWAS of postoperative delirium to date, is substantially better powered than previous analyses and implicates APOE – an established genetic determinant of Alzheimer's disease – in postoperative delirium risk. The lead SNP identified (*rs429358*) remained significant when patients with a pre-existing or subsequent diagnosis of dementia were excluded, as did the significance of the *APOE* gene on MAGMA testing. We have identified additional genes associated with postoperative delirium (*APOC1*, *TOMM40* and *PVRL2*), which were previously reported to be associated with a range of neurocognitive phenotypes including dementia, cognitive function and decline, brain biomarkers and cerebral imaging metrics (Supplementary table 3, Supplementary figure 7). We did not replicate the results of an earlier candidate gene study that identified an association between the cholinergic genes *CHRM2* and *CHRM4* and postoperative delirium [14] (all three identified variants showed null effects, see Supplementary table 6). However, we used a genome-wide approach which has methodological advantages including increased genetic coverage, reduced bias and lower false positive rates and therefore represents a more robust analysis [29].

Post-GWAS follow-up analyses showed that genetic predisposition for Alzheimer's disease is associated with risk of perioperative delirium, including a dose-response effect of *APOE* ε4 allele count. Previous studies investigating the association between *APOE* ε4 and postoperative delirium have shown mixed results. A recent study of 19,331 patients (2086 of whom had postoperative delirium) found *APOE* ε4 carriers to be at increased risk of neurocognitive disorders compared with non-carriers [30]. However, the neurocognitive traits in this study were defined using Phecodes – which include a wider range of medical diagnoses than the more specific ones used in our study [31] – and the authors did not report the timepoint at which outcomes were assessed. Several other studies have found no association [32–34] whilst one small study (29 cases of postoperative delirium) did report increased risk with the ε4 allele [35].

Taken together, these data suggest shared genetic architecture and risk for delirium, whether postoperative or otherwise, and Alzheimer's disease, with multiple clinical implications. Firstly, variants associated with postoperative delirium could be used to risk-stratify patients ahead of surgery to permit alterations to the care pathway such as perioperative care bundles [36]. The use of existing polygenic risk scores for related conditions (e.g. Alzheimer's disease) could add additional predictive benefit. Secondly, the acute occurrence of postoperative delirium might be a marker of underlying neurocognitive vulnerability or an undiagnosed chronic condition. If the prediction of increased postoperative delirium risk is also a risk indicator for future Alzheimer's disease then these patients may benefit from additional monitoring long-term. Finally, our findings of shared biological pathways with Alzheimer's disease

could aid in the development of preventive measures for postoperative delirium. For example, acetylcholinesterase inhibitors are widely used in the treatment of Alzheimer's disease but definitive evidence of benefit for the prevention of postoperative delirium is lacking [37,38]. Identifying the patient group who might benefit from acetylcholinesterase inhibitors could be one important outcome of genetic studies.

The strengths of this study include the use of a large prospective cohort with linked healthcare data that is subject to rigorous quality control and validation procedures. We defined our exposure using published criteria and employed robust statistical methods to deal with the large case-control imbalance. We were also able to extend our findings through a range of post-GWAS analyses using an independent validation cohort. The study does have some limitations. Whilst UK Biobank represents a large cohort of patients there is a recognised "healthy volunteer" selection bias [39] and so the results may not be entirely generalisable to the wider UK population. Any secondary data analysis relying on routinely-collected administrative data is limited by the fields available, with some potentially relevant factors such as ASA physical status grade and type of anaesthesia not recorded. Similarly, the diagnosis of delirium relied upon ICD-10 clinical coding and was not prospectively screened for. Hospital coding for delirium is consistently found to have low sensitivity but excellent specificity [40]. As such we will likely have missed some cases but any resulting bias would have reduced the observed effect, thereby strengthening the validity of our findings. Whilst is also possible that some cases of delirium preceded surgery, the risk of this was minimised as far as possible.

In conclusion, we have used a large national biobank with linked healthcare data to identify six SNPs and four genes associated with increased risk of postoperative delirium. Data from an independent cohort suggests there is shared genetic architecture and risk between postoperative delirium, delirium more broadly, and Alzheimer's disease. These findings have potential clinical benefit through risk stratification based on genotype or polygenic risk score data, early identification of future Alzheimer's disease risk in the perioperative setting, and the identification of biological targets for the prevention of postoperative delirium.

**Authors' contributions**

RAA: study design, data analysis, preparing first and subsequent drafts of the paper;

PY: study design, drafting paper; BG: study design, drafting paper; GK: study design,

drafting paper; TG: study design, drafting paper.

**Acknowledgements**

This research has been conducted using the UK Biobank Resource under Application Number 128619. This includes linked data provided by patients and collected by the NHS as part of their care and support and data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058).

Quality Control filtering of the UK Biobank data used the process described by R.Mitchell, G.Hemani, T.Dudding, L.Corbin, S.Harrison, L.Paternoster[23].

This work was carried out using the computational and data storage facilities of the Advanced Computing Research Centre, University of Bristol (http://www.bristol.ac.uk/acrc/).

**Declaration of interests**

TRG receives funding from GlaxoSmithKline, Biogen and Roche for unrelated research. The other authors declare that they have no conflict of interest.

**Funding**

RAA is funded by a Wellcome Trust GW4-CAT PhD Programme for Health Professionals PhD Fellowship [316275/Z/24/Z]. RAA, PY, GMK and TRG are supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol (RA, TG: MC_UU_00032/3; PY: MC_UU_00032/4; GMK: MC_UU_0032/6). GMK acknowledges additional funding from the Wellcome Trust (grant numbers: 201486/Z/16/Z and 201486/B/16/Z), the Medical Research Council (grant numbers: MR/W014416/1; MR/S037675/1; MR/Z50354X/1; and MR/Z503745/1. PY, TRG, and GMK are also supported by the UK National Institute for Health and Care Research (NIHR) Bristol Biomedical Research Centre (grant number: NIHR 203315). The views expressed are those of the authors and not necessarily those of the UK NIHR or the Department of Health and Social Care.

## References

1. Evered L, Atkins K, Silbert B, Scott DA. Acute peri-operative neurocognitive disorders: a narrative review. *Anaesthesia* 2022; **77**: 34–42.

2. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. *The Lancet* 2014; **383**: 911–22.

3. Gou RY, Hshieh TT, Marcantonio ER et al. One-Year Medicare Costs Associated With Delirium in Older Patients Undergoing Major Elective Surgery. *JAMA Surg.* 2021; **156**: 462–70.

4. MacLullich AMJ, Ferguson KJ, Miller T, de Rooij SEJA, Cunningham C. Unravelling the pathophysiology of delirium: A focus on the role of aberrant stress responses. *J. Psychosom. Res.* 2008; **65**: 229–38.

5. Cerejeira J, Firmino H, Vaz-Serra A, Mukaetova-Ladinska EB. The neuroinflammatory hypothesis of delirium. *Acta Neuropathol. (Berl.)* 2010; **119**: 737–54.

6. Rump K, Adamzik M. Epigenetic Mechanisms of Postoperative Cognitive Impairment Induced by Anesthesia and Neuroinflammation. *Cells* 2022; **11**: 2954.

7. Swarbrick CJ, Partridge JSL. Evidence-based strategies to reduce the incidence of postoperative delirium: a narrative review. *Anaesthesia* 2022; **77**: 92–101.

8. Schenning KJ, Deiner SG. Postoperative Delirium in the Geriatric Patient. *Anesthesiol. Clin.* 2015; **33**: 505–16.

9. Nadelson MR, Sanders RD, Avidan MS. Perioperative cognitive trajectory in adults. *Br. J. Anaesth.* 2014; **112**: 440–51.

10. Goldberg TE, Chen C, Wang Y et al. Association of Delirium With Long-term Cognitive Decline: A Meta-analysis. *JAMA Neurol.* 2020; **77**: 1373–81.

11. Peden CJ, Miller TR, Deiner SG et al. Improving perioperative brain health: an expert consensus review of key actions for the perioperative care team. *Br. J. Anaesth.* 2021; **126**: 423–32.

12. Abdellaoui A, Yengo L, Verweij KJH, Visscher PM. 15 years of GWAS discovery: Realizing the promise. *Am. J. Hum. Genet.* 2023; **110**: 179–94.

13. Rickenbacher M, Reinbold CS, Herms S et al. Genome-wide Association Study of Postoperative Cognitive Dysfunction in Older Surgical Patients. *J. Neurosurg. Anesthesiol.* 2022; **34**: 248.

14. Heinrich M, Sieg M, Kruppa J et al. Association between genetic variants of the cholinergic system and postoperative delirium and cognitive dysfunction in elderly patients. *BMC Med. Genomics* 2021; **14**: 248.

15. Westphal S, Stoppe C, Gruenewald M et al. Genome-wide association study of myocardial infarction, atrial fibrillation, acute stroke, acute kidney injury and delirium after cardiac surgery - a sub-analysis of the RIPHeart-Study. *BMC Cardiovasc. Disord.* 2019; **19**: 26.

16. Bycroft C, Freeman C, Petkova D et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 2018; **562**: 203–9.

17. Kurki MI, Karjalainen J, Palta P et al. FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* 2023; **613**: 508–18.

18. Genetic data | FinnGen.https://www.finngen.fi/en/genetic_data (accessed September 1, 2025).

19. : External Info□: Data_providers_and_dates.https://biobank.ndph.ox.ac.uk/showcase/exinfo.cgi?src= Data_providers_and_dates (accessed October 9, 2024).

20. Abbott TEF, Fowler AJ, Dobbs TD, Harrison EM, Gillies MA, Pearse RM. Frequency of surgical treatment and related hospital procedures in the UK: a national ecological study using hospital episode statistics. *BJA Br. J. Anaesth.* 2017; **119**: 249–57.

21. Bupa - Code Search main.https://codes.bupa.co.uk/procedures (accessed May 12, 2021).

22. Mbatchou J, Barnard L, Backman J et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nat. Genet.* 2021; **53**: 1097–103.

23. Ruth Mitchell GH. UK Biobank Genetic Data: MRC-IEU Quality Control, version 2. *data.bris*, 2019. https://data.bris.ac.uk/data/dataset/1ovaau5sxunp2cv8rcy88688v (accessed October 9, 2024).

24. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* 2017; **8**: 1826.

25. Leeuw CA de, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLOS Comput. Biol.* 2015; **11**: e1004219.

26. Werme J, van der Sluis S, Posthuma D, de Leeuw CA. An integrated framework for local genetic correlation analysis. *Nat. Genet.* 2022; **54**: 274–82.

27. Lambert SA, Wingfield B, Gibson JT et al. Enhancing the Polygenic Score Catalog with tools for score calculation and ancestry normalization. *Nat. Genet.* 2024: 1–6.

28. Ware EB, Faul JD, Mitchell CM, Bakulski KM. Considering the APOE locus in Alzheimer's disease polygenic scores in the Health and Retirement Study: a longitudinal panel study. *BMC Med. Genomics* 2020; **13**: 164.

29. Menon DK, Rosand J. Finding a Place for Candidate Gene Studies in a Genome-Wide Association Study World. *JAMA Netw. Open* 2021; **4**: e2118594.

30. Thedim M, Hu J, Maher M, Wiener-Kronish J, Saxena R, Vacas S. Perioperative polygenic and APOE-based genetic risk assessment for neurocognitive disorders: a biobank study. *Br. J. Anaesth.* 2025; **0**.

31. Denny JC, Bastarache L, Ritchie MD et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. *Nat. Biotechnol.* 2013; **31**: 1102–11.

32. Abelha FJ, Fernandes V, Botelho M et al. Apolipoprotein E e4 allele does not increase the risk of early postoperative delirium after major surgery. *J. Anesth.* 2012; **26**: 412–21.

33. Vasunilashorn S, Ngo L, Kosar CM et al. Does Apolipoprotein E Genotype Increase Risk of Postoperative Delirium? *Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry* 2015; **23**: 1029.

34. Tagarakis GI, Tsolaki-Tagaraki F, Tsolaki M, Diegeler A, Tsilimingas NB, Papassotiropoulos A. The Role of Apolipoprotein E in Cognitive Decline and Delirium after Bypass Heart Operations. *Am. J. Alzheimers Dis. Dementias®* 2007; **22**: 223–8.

35. Leung JM, Sands LP, Wang Y et al. Apolipoprotein E e4 Allele Increases the Risk of Early Postoperative Delirium in Older Patients Undergoing Noncardiac Surgery. *Anesthesiology* 2007; **107**: 406–11.

36. Meco BC, Jakobsen K, De Robertis E et al. A first assessment of the safe brain initiative care bundle for addressing postoperative delirium in the postanesthesia care unit. *J. Clin. Anesth.* 2024; **97**: 111506.

37. Gamberini M, Bolliger D, Lurati Buse GA et al. Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery—A randomized controlled trial*. *Crit. Care Med.* 2009; **37**: 1762.

38. Youn YC, Shin H-W, Choi B-S, Kim S, Lee J-Y, Ha Y-C. Rivastigmine patch reduces the incidence of postoperative delirium in older patients with cognitive impairment. *Int. J. Geriatr. Psychiatry* 2017; **32**: 1079–84.

39. Fry A, Littlejohns TJ, Sudlow C et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am. J. Epidemiol.* 2017; **186**: 1026–34.

40. Chuen VL, Chan ACH, Ma J, Alibhai SMH, Chau V. Assessing the Accuracy of International Classification of Diseases (ICD) Coding for Delirium. *J. Appl. Gerontol.* 2022; **41**: 1485–90.

**Table 1** Participant characteristics for postoperative delirium cases and controls. Numbers are number (proportion), mean (SD) or median (IQR). Additional details can be found in Supplementary table 1.

| | Cases n = 1016 | Controls n = 139,148 | p-value |
|---|---|---|---|
| Age (yr), mean (SD) | 72 (6) | 64 (8) | <0.001 |
| Sex, number (%) | | | <0.001 |
| Female | 384 (38) | 77,244 (56) | |
| Male | 632 (62) | 61,904 (44) | |
| Ethnicity, number (%) | | | 0.2 |
| Asian or Asian British | 9 (0.9) | 2301 (1.7) | |
| Black or Black British | 10 (1.0) | 1644 (1.2) | |
| Chinese | 0 (0) | 239 (0.2) | |
| Mixed | 5 (0.5) | 675 (0.5) | |
| Other ethnic group | 3 (0.3) | 984 (0.7) | |
| White | 978 (97) | 132,676 (96) | |
| Missing | 11 (1.1) | 629 (0.5) | |
| Charlson Comorbidity Index, median (IQR) | 1 (0–3) | 0 (0–1) | <0.001 |
| Missing | 25 (2.5) | 15,817 (11) | |
| Admission method, number (%) | | | <0.001 |
| Elective | 434 (43) | 106,725 (77) | |
| Emergency | 532 (52) | 29,530 (21) | |
| Maternity | 0 (0) | 113 (<0.1) | |
| Not known | 0 (0) | 29 (<0.1) | |
| Transfer | 50 (4.9) | 2751 (2.0) | |
| Surgical specialty, number (%) | | | <0.001 |
| Cardiothoracic surgery | 172 (17) | 5041 (3.6) | |
| General surgery | 196 (19) | 26,436 (19) | |
| Neurosurgery | 55 (5.4) | 5192 (3.7) | |
| Other | 186 (18) | 36,532 (26) | |
| Trauma and orthopaedics | 338 (33) | 53,722 (39) | |
| Urology | 37 (3.6) | 10,628 (7.6) | |
| Vascular | 32 (3.1) | 1597 (1.1) | |

**Table 2** Independent significant single-nucleotide polymorphisms passing genome-wide significance in case-control GWAS of postoperative delirium.

| rsID* | Chr:position | Nearest gene | Function | Effect allele | OR (95% CI) | p |
|---|---|---|---|---|---|---|
| rs429358 | 19:45411941 | *APOE* | exonic | T | 0.56 (0.51-0.62) | $1.40 \times 10^{-26}$ |
| rs157592 | 19:45424514 | *APOC1* | intergenic | A | 0.6 (0.55-0.66) | $2.03 \times 10^{-21}$ |
| rs157582 | 19:45396219 | *TOMM40* | intronic | C | 0.66 (0.6-0.73) | $1.13 \times 10^{-15}$ |
| rs11556505 | 19:45396144 | *TOMM40* | exonic | C | 0.64 (0.58-0.71) | $1.71 \times 10^{-14}$ |
| rs10119 | 19:45406673 | *TOMM40* | UTR3 | G | 0.72 (0.66-0.79) | $6.46 \times 10^{-12}$ |
| rs75627662 | 19:45413576 | *APOE* | downstream | C | 0.74 (0.67-0.82) | $2.11 \times 10^{-8}$ |

*rsID: Reference SNP cluster ID

**Table 1** Results of Local Analysis of [co]Variant Association (LAVA) testing between postoperative delirium GWAS results and FinnGen GWAS summary statistics. Rho represents the local genetic correlation coefficient. $R^2$ represents the proportion of variance in postoperative delirium explained by the comparator phenotype.

| FinnGen phenotype | Rho | $R^2$ | p |
|---|---|---|---|
| Delirium (all) | 0.63 (0.46-0.81) | 0.40 (0.22-0.66) | $3.7 \times 10^{-10}$ |
| Alzheimer's disease | 0.68 (0.57-0.80) | 0.47 (0.32-0.65) | $5.2 \times 10^{-21}$ |

**Table 2** Odds ratio for postoperative delirium by Alzheimer's disease polygenic risk score (PGS) quintile. Results are shown for all 42 polygenic risk scores, adjusted for age and sex, and the subset which did not include the *APOE* region (15 *APOE*-independent scores), adjusted for age, sex and *APOE* ε4 genotype.

| Term | All scores (n=42) | | *APOE*-independent scores (n=15) | |
|---|---|---|---|---|
| | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value |
| PGS quintile 1 | 1.00 (reference) | - | 1.00 (reference) | - |
| PGS quintile 2 | 1.07 (0.85-1.35) | 0.54 | 1.24 (1.00 – 1.53) | 0.052 |
| PGS quintile 3 | 1.25 (1-1.57) | 0.047 | 1.32 (1.07 – 1.62) | 0.01 |
| PGS quintile 4 | 1.49 (1.2-1.85) | <0.001 | 1.24 (1.00 – 1.53) | 0.049 |
| PGS quintile 5 | 2.29 (1.87-2.8) | <0.001 | 1.50 (1.22 – 1.84) | <0.001 |
| Age | 1.22 (1.2-1.23) | <0.001 | 1.22 (1.20 – 1.23) | <0.001 |
| Sex - male | 1.82 (1.6-2.07) | <0.001 | 1.82 (1.60 – 2.07) | <0.001 |
| *APOE* ε4 x1 | - | - | 1.75 (1.53 – 2.00) | <0.001 |
| *APOE* ε4 x2 | - | - | 4.19 (3.25 – 5.41) | <0.001 |

**Figure legends**

**Figure 1** Study flow diagram.

**Figure 2** Manhattan plot of GWAS results. The red line represents a genome-wide significant p value of $5 \times 10^{-8}$.

**Figure 3** Q-Q plot of GWAS results. Genomic inflation factor (λ) 1.017.